NCT02366546 - Investigator Initiated Phase 1 Study of TBI-1301 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2018

Conditions

Solid Tumors

Interventions

DRUG

TBI-1301

TBI-1301(5\*10\^8 or 5\*10\^9) is administered.

DRUG

Cyclophosphamide

Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

DRUG

Fludarabine

Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.

Trial Locations (1)

Mie University Hospital, Tsu